Login to Your Account

Rigel Takes Hit on R788 Data, But Partnering Thesis Intact

By Catherine Hollingsworth

Monday, July 27, 2009
Rigel Pharmaceuticals Inc. said a midstage study of rheumatoid arthritis drug R788 missed the mark, a development that might complicate partnership talks but won't end them. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription